Results 81 to 90 of about 35,475 (187)

Voriconazole Treatment Schedule.

open access: yes, 2013
Voriconazole Treatment Schedule.
Joris Veltman (431438)   +10 more
core   +1 more source

Voriconazole is a safe and effective anti-fungal prophylactic agent during induction therapy of acute myeloid leukemia

open access: yesIndian Journal of Medical and Paediatric Oncology, 2016
Background: Antifungal prophylaxis (AFP) reduces the incidence of invasive fungal infections (IFIs) during induction therapy of acute myeloid leukemia (AML). Posaconazole is considered the standard of care.
Akash Shah   +8 more
doaj   +1 more source

Voriconazole Induced Bradycardia

open access: yes, 2013
Voriconazole is a triazole antifungal drug that is used to treat invasive fungal infections, especially aspergillus. Here, we report two children who had severe bradycardia associated with voriconazole at a dose of 12 mg/kg per day.
Celkan, Tiraje   +4 more
core   +1 more source

Histone deacetylase inhibitors as venetoclax‐sensitising partners in acute myeloid leukaemia: Mechanisms, pharmacology and translational perspectives

open access: yesBritish Journal of Pharmacology, Volume 183, Issue 21, Page 6261-6290, November 2026.
Abstract Venetoclax combined with hypomethylating agents has improved treatment for older or unfit patients with acute myeloid leukaemia (AML), but resistance and relapse remain common. This review analyses the rationale for combining venetoclax with inhibitors of histone deacetylase (HDAC).
Jaebok Lee, Marc Diederich
wiley   +1 more source

Voriconazole-induced periostitis in a patient with overlap syndromes. [PDF]

open access: yes, 2014
A 52-year-old woman with overlap syndrome and interstitial pneumonia underwent immunosuppressive therapy and she was suspected to suffer from pulmonary aspergillosis.
Yasoda, Akihiro   +3 more
core   +1 more source

Voriconazole-induced periostitis

open access: yes, 2019
In this case report, a 49-year-old man was diagnosed with influenza-associated invasive aspergillosis. Voriconazole therapy was initiated and adjusted to meet therapeutic range.
Katzenstein, Terese Lea   +3 more
core   +1 more source

Azole‐Resistant Aspergillosis: An Emerging Diagnostic and Therapeutic Challenge in Paediatrics

open access: yesMycoses, Volume 69, Issue 11, November 2026.
ABSTRACT Introduction Invasive aspergillosis (IA) represents one of the most frequent invasive fungal infections in paediatric patients with risk factors. An increase in cases of azole‐resistant IA has been reported in adult patients. The aim of this study is to present a series of 11 cases of paediatric patients with this pathology.
Natalia Mendoza‐Palomar   +14 more
wiley   +1 more source

Successful treatment of Chrysosporium keratitis with voriconazole

open access: yes, 2017
Onsiri Thanathanee, Chavakij Bhoomibunchoo, Orapin Anutarapongpan, Olan Suwan-apichon, Yosanan Yospaiboon KKU Eye Center, Department of Ophthalmology, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand Objective: To report a ...
Thanathanee O   +4 more
core  

Voriconazole successfully treats chytridiomycosis in frogs

open access: yes
Chytridiomycosis is a devastating disease and is a key cause of amphibian population declines around the world. Despite active research on this amphibian disease system for over 2 decades, we still do not have treatment methods that are safe and that can
Ballesteros, Sofia   +3 more
core   +1 more source

Real‐World Use of Rezafungin for the Treatment of Challenging Aspergillus Infections

open access: yesMycoses, Volume 69, Issue 11, November 2026.
ABSTRACT Background Aspergillus infections can pose significant treatment challenges, due in part to increasing triazole resistance. Clinical insight is needed to understand the potential for rezafungin, a next‐generation echinocandin with once‐weekly dosing, to address some limitations of current treatments for Aspergillus infections.
Neil Stone   +9 more
wiley   +1 more source

Home - About - Disclaimer - Privacy